Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Interim Management Statement

18 Nov 2011 07:00

RNS Number : 3240S
Evolution Group PLC
18 November 2011
 



Embargoed until 7.00am 18 Nov 2011

 

The Evolution Group Plc

(the "Evolution Group", the "Group", the "Company")

Interim Management Statement

 

Evolution Group, the listed investment bank and private client investment management group, today announces its second Interim Management Statement for the financial year ending 31 December 2011, as required by the UK Listing Authority's Disclosure and Transparency Rule 4.3. This relates to the period from 1 July 2011 to today's date.

 

Investec Offer

 

As announced on 27th October 2011, the Group's shareholders voted by the requisite majority to approve Investec plc's acquisition of the Group. The hearing of the petition to the Court to sanction the Court sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme") and to confirm the related Capital Reduction is expected to take place on 13 December 2011, although this is dependent on certain conditions to the Scheme having been satisfied by that date, including the receipt of requisite regulatory and anti-trust clearances.

 

Subject to the Court sanctioning the Scheme and the satisfaction of certain other outstanding conditions, it is expected that the last day for dealings in Evolution Shares will be 13 December 2011 and the Scheme will become effective on 14 December 2011. If the Scheme becomes effective on 14 December 2011, it is expected that the new Investec plc shares to be allotted to existing Evolution Group shareholders pursuant to the Scheme will be admitted to the official list of the UK Listing Authority and to trading on the London Stock Exchange's Main Market for listed securities on the 14 December 2011 and the listing of Evolution will be cancelled on 14 December 2011.

 

Group performance

 

Despite ongoing tough market conditions, we are pleased to announce that the Group is line to meet the Board's expectations regarding trading performance.

 

Private Clients1

 

As announced on the 20 October 2011, Williams de Broë completed the acquisition of BNP Paribas Private Investment Management Limited from BNP Paribas Wealth Management S.A.

 

Although still in its infancy the acquisition is proceeding smoothly, bringing ÂŁ1.5bn of new Assets under Management to the business.

 

Our Private client business also continued to see momentum in organic new fund sales, with Q3 gross inflows of ÂŁ96m (Q3 2010: ÂŁ95m), whilst also continuing to attract high calibre professionals to its investment management and business development teams.

 

As a result of these organic and inorganic inflows offsetting recent market falls Assets under Management have grown to be £7.1bn at the end of October 2011, up 18% from £6.0bn at 30 June 2011. We believe this increase in Assets under Management, combined with a scalable business model, leaves Williams de Broë well placed to further increase its profits and margins.

 

Investment Banking2

 

Our Investment Banking division has been significantly impacted by the recent turbulent market conditions and the inherent uncertainty over the Group's future following Investec's initial offer on the 3 August.

 

As a result of these two factors, income is considerably down in Q3, resulting in the business accruing a year to date loss at the adjusted operating level.

 

Due to the current depressed levels of income within the business, Management has taken action to reduce the cost base from Q4 onwards. This has been achieved by reducing headcount by 60 employees and continuing to have a disciplined approach to all areas of discretionary expenditure.

 

Despite these recent losses, the corporate finance and debt capital markets ("DCM") pipelines remain strong, including seven IPOs, six further retail bond mandates and a number of secondary equity raisings expected to complete before the year end.

 

To date in 2011, the investment banking division has acted on 10 equity capital market transactions, with a total of ÂŁ1.4bn raised by its clients. Our DCM business has completed three mandates during the period, notably including Tesco Bank (raising ÂŁ125m), Places for People (the first social housing retail bond issue, raising ÂŁ145m) and National Grid (the first RPI-linked retail bond, raising ÂŁ282.5m).

 

 

Notes

1The results of Private Clients are defined as those arising from Williams de Broë Limited, WDB Asset Management Limited, WDB AssetMaster Management Company Limited and from Williams de Broë Private Investment Management Limited (Formally BNP Paribas Private Investment Management Limited).

2The results of Investment Banking are defined as those arising from Evolution Securities Limited, its subsidiary Evolution Securities (US) Inc. ("ESUS") and Darwin Strategic Limited ("Darwin").

 

Forward looking statements

 

This interim management statement may contain forward-looking statements with respect to the financial condition, results, operations and businesses of The Evolution Group Plc. Such statements and forecasts involve risk and uncertainty because they relate to events and depend upon circumstances that will occur in the future. There are a number of factors that could cause actual results or developments to differ materially from those expressed or implied by forward-looking statements and forecasts. Forward-looking statements and forecasts are based on the Directors' current view and information known to them at the date of this statement. The Directors do not make any undertaking to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Nothing in this interim management statement should be construed as a profit forecast.

 

-Ends-

 

For further information, please contact:

 

The Evolution Group Plc

Alex Snow, Chief Executive Officer

 

020 7071 4300

 

 

Pelham Bell Pottinger (Financial PR to Investec)

020 7861 3925

Victoria Geoghegan

 

 

Notes to Editors:

 

The Evolution Group Plc

The Evolution Group is the holding company of Evolution Securities Limited, Williams de Broë Limited and Evolution Securities China Limited. Founded in April 2001 and originally listed on AIM, the Evolution Group joined the LSE Official List in 2003; the Group currently has a market capitalisation of approximately £180 million.

 

Evolution Securities Limited is a leading investment bank focused on UK mid cap public companies. It provides a full range of investment banking services including equity research, institutional sales and trading, market making and corporate finance advice. Evolution Securities Limited has over 70 retained corporate clients. It is authorised and regulated by the Financial Services Authority.

 

Williams de Broë Limited is one of the UK's leading and fastest growing private client investment managers, with offices in Bath, Birmingham, Bournemouth, Edinburgh, Exeter, Guildford and London. Williams de Broë Limited is authorised and regulated by the Financial Services Authority.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSFMMMMVNVGMZM
Date   Source Headline
10th Oct 202211:05 amRNSSecond Price Monitoring Extn
10th Oct 202211:00 amRNSPrice Monitoring Extension
10th Oct 20227:00 amRNSSFX-01 licensing deal for up to $160.5m
29th Sep 20227:00 amRNSRegulatory approval for healthy volunteer study
22nd Jul 20227:00 amRNSResult of AGM
14th Jul 202212:43 pmRNSInvestor Presentation
6th Jul 202212:25 pmRNSNotice of AGM
13th Jun 20227:00 amRNSCollaboration with University of Michigan
8th Jun 20227:00 amRNSFull Year Results
7th Jun 20227:00 amRNSNotice of Results
25th May 20227:00 amRNSCollaboration with Università Sapienza di Roma
29th Apr 20222:39 pmRNSHolding(s) in Company
15th Mar 20222:05 pmRNSSecond Price Monitoring Extn
15th Mar 20222:00 pmRNSPrice Monitoring Extension
7th Mar 20227:00 amRNSManchester Breast Centre collaboration expanded
18th Jan 20227:00 amRNSOption over new sulforaphane analogues
11th Jan 20227:00 amRNSProgress with UK and US regulators for 2022 trials
30th Dec 202111:35 amRNSHolding(s) in Company
8th Dec 20212:08 pmRNSGrant of Options
7th Dec 20217:00 amRNSHalf-year Report
23rd Nov 20217:00 amRNSNotice of Results
10th Nov 20217:00 amRNSPublication of data on SFX-01 in glioblastoma
19th Oct 20212:39 pmRNSHolding(s) in Company
20th Sep 20217:00 amRNSPublication of data in glioblastoma cells
2nd Sep 20212:32 pmRNSHolding(s) in Company
2nd Sep 20212:06 pmRNSSecond Price Monitoring Extn
2nd Sep 20212:00 pmRNSPrice Monitoring Extension
2nd Sep 202111:05 amRNSSecond Price Monitoring Extn
2nd Sep 202111:01 amRNSGlioma Orphan Drug designation granted by FDA
2nd Sep 202111:00 amRNSPrice Monitoring Extension
25th Aug 20214:42 pmRNSHolding(s) in Company
24th Aug 20214:41 pmRNSSecond Price Monitoring Extn
24th Aug 20214:36 pmRNSPrice Monitoring Extension
9th Aug 20215:06 pmRNSHolding(s) in Company
20th Jul 202111:57 amRNSHolding(s) in Company
16th Jul 20211:50 pmRNSHolding(s) in Company
14th Jul 202110:23 amRNSHolding(s) in Company
13th Jul 20215:02 pmRNSResult of AGM and Business Update
13th Jul 20213:55 pmRNSHolding(s) in Company
13th Jul 20217:00 amRNSEarly data for SFX-01 in leukaemia cell lines
13th Jul 20217:00 amRNSGlioma Orphan Drug application submitted to US FDA
9th Jul 202111:05 amRNSSecond Price Monitoring Extn
9th Jul 202111:00 amRNSPrice Monitoring Extension
9th Jul 20217:00 amRNSInterim Safety and Futility Analysis - STAR trial
18th Jun 20217:00 amRNSPosting of Annual Report and Notice of AGM
15th Jun 20217:00 amRNSFinal Results
14th Jun 20217:00 amRNSProgress with Glioma/Glioblastoma programme
14th Jun 20217:00 amRNSProgress on metastatic breast cancer programme
26th Apr 20217:00 amRNSAppointment of Chief Medical Officer
7th Apr 20217:00 amRNSPublication on sulforaphane in COVID-19

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.